Herpes zoster

Published on 19/03/2015 by admin

Filed under Dermatology

Last modified 19/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1518 times

Herpes zoster

Rana Majd Mays, Erik T. Petersen, Rachel A. Gordon and Stephen K. Tyring

Evidence Levels:  A Double-blind study  B Clinical trial ≥ 20 subjects  C Clinical trial < 20 subjects  D Series ≥ 5 subjects  E Anecdotal case reports

image

Reactivation of latent varicella zoster virus (VZV) produces the clinical syndrome herpes zoster (shingles), which manifests as a unilateral eruption along a single dermatome and is usually preceded by prodromal pain and paresthesia. The eruption lasts around seven to 10 days, and progresses from erythematous macules and papules to vesicles, then pustules, and finally crusts over. One of the most common complications of herpes zoster is postherpetic neuralgia (PHN), which is dermatomal pain persisting longer than 3 months.

Management strategy

Early treatment – within the first 72 hours of vesicle formation – is important for antiviral efficacy, time to lesion healing, and minimizing zoster-associated pain (although initiating treatment after 72 hours may still be effective). Acyclovir, valacyclovir, and famciclovir are guanosine analogs that are phosphorylated by thymidine kinase to a triphosphate form that inhibits viral DNA polymerase. The oral bioavailability of the antivirals determines the number of daily administrations. Patient compliance tends to decrease as the number of daily administrations increases. The most common side effects seen are nausea, headache, and gastrointestinal upset, but these drugs are otherwise safe and well tolerated. Patients with renal insufficiency will need an adjusted dose, as these medications are excreted by the kidneys.

Acyclovir-resistant VZV infections have been reported in immunocompromised patients (i.e., AIDS, transplant patients) and in these cases foscarnet (given intravenously 40 mg/kg three times daily) can be used as an alternative.

Acutely, corticosteroids may reduce zoster-associated pain, but they are associated with a risk of serious adverse events and have shown no benefit in reducing time to complete cessation of pain.

Current therapeutic options for PHN include the anticonvulsants gabapentin and pregabalin, opioid analgesics, tricyclic antidepressants (Table 101.1), lidocaine patch 5%, and capsaicin cream. Choice of therapy should be guided by considering a patient’s comorbidities, drug adverse event profiles, and preference. Combination therapy is common in clinical practice, but there is no evidence base to support this practice.

Table 101.1

Treatment options for postherpetic neuralgia

Drug class Examples Initial daily dose (mg) Titration to maximum dose
Anticonvulsants Gabapentin 100–300 Start qhs and increase to tid dosing; increase by 100–300 mg every 3 days to total dose of 1800–2400 mg/day
Pregabalin 150 Titrate up to 300 or 600 mg/day
Opioids Hydrocodone 5–10 No titration
Oxycodone (extended release) 20 Titrate up to 60 mg daily
Tricyclic antidepressants Nortriptyline 10–25 Increase by 10–25 mg weekly, with a target dose of 75–150 mg daily; single dose or two divided doses
Amitriptyline 10–25 Titrate up to 100 mg daily; single dose
Desipramine 10–25 Increase every 3 days as needed up to 150 mg daily; single dose

image

Vaccination of patients aged 50 years and over with VZV is the most promising option for the prevention of herpes zoster. Administration of gabapentin in conjunction with antivirals (and analgesics) during the acute phase of zoster may offer further protection against PHN. Asymptomatic reactivation of the VZV and contact with patients with chickenpox may enhance cell-mediated immunity.

Related posts:

Capillaritis (pigmented purpuric dermatoses) Xanthomas Mastocytoses Sporotrichosis Discoid lupus erythematosus Bites and stings